GlassScriptPhysician profile
Sheena K Jain
NPI 1770746604
$334.48
in general payments reported to CMS, 2019-2025
10 companies · $50.26 in 2025
The $50.26 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.91 · 2020: $40.90 · 2022: $59.63 · 2023: $32.15 · 2024: $82.63 · 2025: $50.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $68.30 | 2019-2025 | Optune Gio |
| Siemens Medical Solutions USA, INC. | $54.48 | 2024-2025 | Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Accuray Incorporated | $35.50 | 2024 | |
| Foundation Medicine, INC. | $34.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $32.15 | 2023 | Libtayo |
| Portola Pharmaceuticals, LLC | $27.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.22 | 2019 | |
| Celgene Corporation | $24.16 | 2020 | |
| Seagen INC. | $16.74 | 2020 | |
| Glaxosmithkline, LLC. | $16.70 | 2024 | Zejula, Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.